For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
6
views
39
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      0
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Patent Highlights June–July 2023

      Author(s):   1
      Publication date (Electronic):
      Journal: Pharmaceutical Patent Analyst
      Publisher: Informa UK Limited

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: not found
          • Article: not found

          FSP1 is a glutathione-independent ferroptosis suppressor

          Sebastian Doll, Florêncio Porto Freitas, Ron Shah … (2019)
          Article 0 comments Cited 1177 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

            Teeara Berry, William Luther, Namrata Bhatnagar … (2012)
            The ALK(F1174L) mutation is associated with intrinsic and acquired resistance to crizotinib and cosegregates with MYCN in neuroblastoma. In this study, we generated a mouse model overexpressing ALK(F1174L) in the neural crest. Compared to ALK(F1174L) and MYCN alone, co-expression of these two oncogenes led to the development of neuroblastomas with earlier onset, higher penetrance, and enhanced lethality. ALK(F1174L)/MYCN tumors exhibited increased MYCN dosage due to ALK(F1174L)-induced activation of the PI3K/AKT/mTOR and MAPK pathways, coupled with suppression of MYCN pro-apoptotic effects. Combined treatment with the ATP-competitive mTOR inhibitor Torin2 overcame the resistance of ALK(F1174L)/MYCN tumors to crizotinib. Our findings demonstrate a pathogenic role for ALK(F1174L) in neuroblastomas overexpressing MYCN and suggest a strategy for improving targeted therapy for ALK-positive neuroblastoma. Copyright © 2012 Elsevier Inc. All rights reserved.
            Article 0 comments Cited 131 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review

              Saartje Uyttebroek, Baixing Chen, Jolien Onsea … (2022)
              According to the latest reports from WHO, the incidence of antibiotic-resistant bacterial infections is increasing worldwide, resulting in increased morbidity and mortality and a rising pressure on health-care systems. However, the development of new antibiotics is an expensive and time-consuming process, urging scientists to seek alternative antimicrobial strategies. Over the past few decades, the concept of therapeutic administration of bacteriophages (also known as phages) has gained popularity worldwide. Although conceptually promising, the widespread implementation of phage therapy in routine clinical practice is restricted by the scarcity of safety and efficacy data obtained according to the strict standards of the applicable clinical trial regulations. In this systematic review, we list clinical data published between Jan 1, 2000 and Aug 14, 2021 on the safety and efficacy of phage therapy for difficult-to-treat bacterial infections, and provide an overview of trials and case studies on the use of phage therapy in several medical disciplines.
              Article 0 comments Cited 78 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Hermann AM Mucke: (View ORCID Profile)
                Journal
                Title: Pharmaceutical Patent Analyst
                Abbreviated Title: Pharmaceutical Patent Analyst
                Publisher: Informa UK Limited
                ISSN (Print): 2046-8954
                ISSN (Electronic): 2046-8962
                Publication date (Electronic): March 18 2024
                Affiliations
                [1 ]H.M. Pharma Consultancy, A-1160 Wien, Austria
                Article
                DOI: 10.4155/ppa-2023-0035
                SO-VID: 5940c760-8030-4e0c-b05b-17cdae06131e
                Copyright © © 2024
                History

                Data availability:

                Comments

                Comment on this article